Ursodiol costs far more than you’d expect for a generic drug that’s been around for decades. The retail price for a 60-capsule supply of 300mg capsules sits around $441 before discounts, though coupon prices can bring that down to roughly $30 to $46. The gap between those numbers tells much of the story: ursodiol’s pricing reflects a combination of animal-sourced raw materials, a complicated manufacturing process, a small number of suppliers, and a history of dramatic price hikes that never fully reversed.
What Ursodiol Is Made From
Ursodiol (ursodeoxycholic acid, or UDCA) isn’t a simple molecule you can synthesize cheaply from common chemicals. It’s a bile acid, and the raw materials used to produce it are almost exclusively animal-derived. The three main starting compounds, cholic acid, chenodeoxycholic acid, and hyodeoxycholic acid, are all extracted from animal bile. Cholic acid is the most abundant and least expensive of these, making it the most commonly used starting material.
The chemical conversion from raw bile acid to finished ursodiol requires multiple reaction steps. Starting from chenodeoxycholic acid, which offers the simplest route, the process involves oxidation followed by selective reduction, yielding about 70% of the desired product. Starting from cholic acid requires additional steps because the molecule needs more structural modification. Using hyodeoxycholic acid is cheaper on the raw material side but adds extra synthetic steps to swap out one chemical group for another, dropping overall yield to around 26%.
Researchers have explored plant-based alternatives. One route starts from a steroid compound derived from plants and reaches ursodiol in eight steps with an overall yield of about 35%. Another plant-based route achieves 59% yield in six steps. But these newer methods haven’t displaced animal-sourced production at commercial scale, meaning the supply chain still depends on animal bile availability, which fluctuates with livestock industry output.
The 2013-2014 Price Spike
Ursodiol experienced what the U.S. Government Accountability Office classified as an “extraordinary price increase” between 2013 and 2014. In a study of generic drug pricing under Medicare Part D, the GAO flagged ursodiol 300mg capsules as one of the drugs whose price jumped by at least 100% in a single year. That threshold, a doubling or more in one year, placed ursodiol among a relatively small group of generics that saw dramatic spikes during that period.
These kinds of jumps in the generic market typically happen when the number of manufacturers drops to just one or two. With so few companies competing, there’s little pressure to keep prices low. And once a generic price rises sharply, it rarely falls all the way back. The new higher price becomes the baseline that future pricing builds on.
Limited Competition Among Manufacturers
The brand-name versions of ursodiol, Urso and Urso Forte, have both been discontinued. Urso Forte’s 500mg tablet was originally approved in 2004 under AbbVie, but all brand formulations have since left the market. That leaves only generic manufacturers, and the number of companies actually producing ursodiol capsules and tablets at any given time tends to be small.
A drug doesn’t need patent protection to stay expensive. When only a handful of generic manufacturers are in the market, pricing behaves more like a limited-competition product than a true commodity. Each manufacturer has to maintain a supply of animal-derived raw materials, run a multi-step chemical synthesis, and meet FDA quality standards for a bile acid product. Those barriers discourage new entrants, especially for a drug with a relatively small patient population.
A Small Patient Population
Ursodiol is primarily prescribed for two conditions: dissolving certain gallstones in people who can’t have surgery, and treating primary biliary cholangitis (PBC), a chronic liver disease. PBC is a rare condition, and while gallstone dissolution is more common, most people with gallstones end up having surgery rather than taking months of medication. This means total market demand for ursodiol is modest compared to blockbuster generics like blood pressure or cholesterol medications.
Lower demand creates a cycle that keeps prices elevated. Manufacturers can’t spread their fixed costs across millions of prescriptions, so each unit needs to carry a higher margin. And because patients with PBC often need the drug indefinitely, they have little choice but to pay whatever the market charges. Newer PBC treatments like obeticholic acid, elafibranor, and seladelpar exist, but they’re branded specialty drugs designed mainly for patients who don’t respond to ursodiol, not cheaper alternatives to it.
What You Actually Pay
The sticker price and the price you pay can be wildly different. Retail pricing for 60 capsules of ursodiol 300mg runs about $441. But pharmacy discount programs and manufacturer coupons can cut that by 89% to 93%, bringing the cost down to $30 to $46 for the same quantity. Per-capsule pricing through U.S. pharmacies with coupons lands around $0.50 to $0.62.
International pricing tells a more complicated story than you might expect. Canadian and UK online pharmacies list ursodiol at roughly $0.85 to $2.00 per tablet depending on the source and quantity ordered. That means with a good coupon, U.S. prices can actually be comparable to or lower than some international options, a rare situation in pharmaceutical pricing. The catch is that the coupon price isn’t what most people encounter at the pharmacy counter. Without a discount card, you’re looking at that $441 retail figure, and insurance copays vary enormously depending on your plan’s formulary tier.
If you’re paying out of pocket, pharmacy discount tools like GoodRx or the programs listed on PharmacyChecker are worth checking every time you refill. Prices vary significantly between pharmacies, and the spread between the cheapest and most expensive option for the same drug in the same city can be tenfold.
Why the Price Stays High
Ursodiol’s pricing is a case study in how generic drugs can remain expensive even without patent protection. The animal-sourced raw materials are subject to supply fluctuations. The multi-step synthesis keeps manufacturing costs above average. A small number of producers means limited competition. The patient population is too small to attract aggressive generic competition. And a 100%-plus price spike in 2013-2014 reset the baseline to a higher level that the market never corrected.
None of these factors alone would make ursodiol unaffordable. Together, they create a pricing environment where a decades-old generic drug costs hundreds of dollars at retail, even though the active ingredient has been used in medicine since the 1970s and has no remaining patent exclusivity.